Shares of Himax Technologies, Inc. (ADR)(NASDAQ:HIMX) slumped 16% on Tuesday after Bank of America downgraded the flat-panel chip maker from buy to underperform. So what: Along with the two-notch downgrade, analyst Dan Heyler slashed his price target to $12.50 (from $17.58), representing about 7% worth of downside to yesterday’s close. So while contrarians might be attracted to the stock’s sharp pullback in recent weeks, Heyler’s call could reflect strengthening skepticism on Wall Street over Himax’s true growth potential. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) shares after opening at $12.15 moved to $12.50 on last trade day and at the end of the day closed at $11.86. Company price to sales ratio in past twelve months was calculated as 2.64 and price to cash ratio as 13.69. Himax Technologies, Inc. (ADR) (NASDAQ:HIMX) showed a negative weekly performance of -21.25%.
Shares of Wet Seal (NASDAQ:WTSL) have earned an average recommendation of “Hold” from the eight analysts that are currently covering the company, Analyst Ratings Network reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $3.35. The Wet Seal, Inc. (NASDAQ:WTSL) shares fell -11.90% in last trading session and ended the day on $1.11. WTSL return on equity ratio is recorded as -81.20% and its return on assets is -43.80%. The Wet Seal, Inc. (NASDAQ:WTSL) yearly performance is -63.25%.
Geron Corporation (NASDAQ:GERN) is a clinical stage bio pharma company that involved in developing a 1st-in-class telomerase-inhibitor, that is named imetelstat, in hematologic myeloid malignancies. Telomerase is the enzyme that permits the cancer cells in the body to maintain their telomere length; this provides them with the capacity for their limitless cellular-replication. Imetelstat is the specific inhibitor of telomerase. Geron Corporation (NASDAQ:GERN) focuses on developing its drug imetelstat in the treatment of one/more hematologic-myeloid malignancies, like myelofibrosis (MF), myelodysplastic-syndromes (MDS)/acute myelogenous-leukemia (AML). Geron Corporation (NASDAQ:GERN) shares moved down -5.70% in last trading session and was closed at $3.55, while trading in range of $ 3.48 – 3.60.Geron Corporation (NASDAQ:GERN) year to date performance is -54.64%.
The Shareholders Foundation announces that an investor, who purchased shares of CytRx Corporation (NASDAQ:CYTR), filed a lawsuit in the U.S. District Court for the CentralDistrict of California over alleged violations of Federal Securities Laws by CytRx inconnection with certain allegedly false and misleading statements made between November 22, 2013 and March 13, 2014. CytRx Corporation (NASDAQ:CYTR) weekly performance is -9.56%. On last trading day company shares ended up $3.69. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average is -39.15%. Analysts mean target price for the company is $11.00.
Leave a Reply